CERT Certara

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday November 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET.

Investors interested in listening to the conference call are required to . It is recommended to register at least one day in advance.

Certara also announced that Company management will participate in the upcoming Stephens Annual Investment Conference. Company management will present at 2:00PM CT on Wednesday, November 15th.

Live and archived webcasts of the events will be available on the “Investors” section of the Certara website at .

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries. Visit us at .

Investor Relations Contact:

David Deuchler

Gilmartin Group

Media Contact:

Daniel Yunger

Kekst CNC



EN
11/10/2023

Underlying

CERTCertara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE
Free
CERT CERTARA

Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Su...

Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster Solution delivers a 50% reduction in time spent drafting mapping specifications, according to internal measurements RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the availability of . The solution enables clinical and statistical programmers to efficiently create, reuse, and manage required data specifications for creating the CDISC Study Data Tabulation Model (SDTM) and Analysis Data Model (ADaM) datasets. These dataset...

September 4, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: Baird Global Healthcare ConferenceDate and Time: Tuesday, September 9 at 10:15 a.m. ET Morgan Stanley 23rd Annual Global Healthcare ConferenceDate and Time: Wednesday, September 10 at 12:20 p.m. ET Live webcasts for each of the conferences will be available on Certara’s investor relations website at and will...

September 2, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Reports Second Quarter 2025 Financial Results 

Certara Reports Second Quarter 2025 Financial Results  Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million, compared to $38.2 million in the second quarter of 2024, representing growth of 22%.Service revenue ...

August 6, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Simcyp® Simulator Becomes First and Only Software Platform to ...

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. Certara is the first company to receive EMA qualification for a PBPK modeling platform, and Simcyp is the only software to hold this designation. The recognition follows a rigorous multi-year, collaborative engagement between ...

August 4, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advan...

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-gene...

July 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch